Edward P. Acosta - Publications

University of Alabama, Birmingham, Birmingham, AL, United States 
Pharmacology, Pharmaceutical Chemistry

116 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Namazi G, Fajnzylber JM, Aga E, Bosch R, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, et al. The Control of HIV after Antiretroviral Medication Pause (CHAMP) study: post-treatment controllers identified from 14 clinical studies. The Journal of Infectious Diseases. PMID 30085241 DOI: 10.1093/Infdis/Jiy479  0.32
2016 Cressey TR, Hazra R, Wiznia A, Foca M, Jean-Philippe P, Graham B, King JR, Britto P, Carey VJ, Acosta EP, Yogev R. Pharmacokinetics of Unboosted Atazanavir in Treatment-Experienced HIV-infected Children, Adolescents and Young Adults. The Pediatric Infectious Disease Journal. PMID 27583590 DOI: 10.1097/Inf.0000000000001320  0.36
2016 Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Fletcher CV, Acosta EP. Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults. Journal of the Pediatric Infectious Diseases Society. PMID 27103489 DOI: 10.1093/Jpids/Piw017  0.8
2015 Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, Eron JJ, Berzins B, Robertson K, Landay A, Ofotokun I, Brown T. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 26060295 DOI: 10.1093/Cid/Civ455  0.76
2015 Rizk ML, Du L, Bennetto-Hood C, Wenning L, Teppler H, Homony B, Graham B, Fry C, Nachman S, Wiznia A, Worrell C, Smith B, Acosta EP. Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age. Journal of Clinical Pharmacology. 55: 748-56. PMID 25753401 DOI: 10.1002/Jcph.493  0.76
2014 Larson KB, Wang K, Delille C, Otofokun I, Acosta EP. Pharmacokinetic enhancers in HIV therapeutics. Clinical Pharmacokinetics. 53: 865-72. PMID 25164142 DOI: 10.1007/S40262-014-0167-9  0.76
2014 Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M. Raltegravir pharmacokinetics in neonates following maternal dosing. Journal of Acquired Immune Deficiency Syndromes (1999). 67: 310-5. PMID 25162819 DOI: 10.1097/Qai.0000000000000316  0.76
2014 Delille CA, Pruett ST, Marconi VC, Lennox JL, Armstrong WS, Arrendale RF, Sheth AN, Easley KA, Acosta EP, Vunnava A, Ofotokun I. Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. Journal of Clinical Pharmacology. 54: 1063-71. PMID 24691856 DOI: 10.1002/Jcph.298  0.76
2014 Li JZ, Chapman B, Charlebois P, Hofmann O, Weiner B, Porter AJ, Samuel R, Vardhanabhuti S, Zheng L, Eron J, Taiwo B, Zody MC, Henn MR, Kuritzkes DR, Hide W, ... ... Acosta EP, et al. Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. Plos One. 9: e90485. PMID 24603872 DOI: 10.1371/Journal.Pone.0090485  0.76
2014 Wang K, D'Argenio DZ, Acosta EP, Sheth AN, Delille C, Lennox JL, Kerstner-Wood C, Ofotokun I. Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients. Clinical Pharmacokinetics. 53: 361-71. PMID 24311282 DOI: 10.1007/S40262-013-0122-1  0.76
2014 Acosta EP, Grigsby PL, Larson KB, James AM, Long MC, Duffy LB, Waites KB, Novy MJ. Transplacental transfer of Azithromycin and its use for eradicating intra-amniotic ureaplasma infection in a primate model. The Journal of Infectious Diseases. 209: 898-904. PMID 24179112 DOI: 10.1093/Infdis/Jit578  0.76
2014 Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A, et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 58: 413-22. PMID 24145879 DOI: 10.1093/Cid/Cit696  0.76
2013 James AM, King JR, Ofotokun I, Sheth AN, Acosta EP. Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives. Journal of Experimental Pharmacology. 5: 55-64. PMID 27186136 DOI: 10.2147/JEP.S45308  0.36
2013 Larson KB, King JR, Acosta EP. Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics. Adolescent Health, Medicine and Therapeutics. 4: 79-87. PMID 24600298 DOI: 10.2147/Ahmt.S29462  0.36
2013 Johnson DH, Sutherland D, Acosta EP, Erdem H, Richardson D, Haas DW. Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study. Plos One. 8: e82672. PMID 24349334 DOI: 10.1371/Journal.Pone.0082672  0.76
2013 Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. The Journal of Infectious Diseases. 208: 884-91. PMID 23801609 DOI: 10.1093/Infdis/Jit272  0.76
2013 Kimberlin DW, Acosta EP, Prichard MN, Sánchez PJ, Ampofo K, Lang D, Ashouri N, Vanchiere JA, Abzug MJ, Abughali N, Caserta MT, Englund JA, Sood SK, Spigarelli MG, Bradley JS, et al. Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. The Journal of Infectious Diseases. 207: 709-20. PMID 23230059 DOI: 10.1093/Infdis/Jis765  0.76
2013 Baheti G, King JR, Acosta EP, Fletcher CV. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults. Aids (London, England). 27: 221-5. PMID 23032419 DOI: 10.1097/Qad.0B013E32835A9A2D  0.76
2013 Johnson DH, Gebretsadik T, Shintani A, Mayo G, Acosta EP, Stein CM, Haas DW. Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose. British Journal of Clinical Pharmacology. 75: 997-1006. PMID 22957905 DOI: 10.1111/J.1365-2125.2012.04454.X  0.76
2013 Okulicz JF, Grandits GA, French JA, Perucca E, George JM, Landrum ML, Acosta EP, Birbeck GL. The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study. Epilepsy Research. 103: 245-53. PMID 22835761 DOI: 10.1016/J.Eplepsyres.2012.07.009  0.76
2012 Grigsby PL, Novy MJ, Sadowsky DW, Morgan TK, Long M, Acosta E, Duffy LB, Waites KB. Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. American Journal of Obstetrics and Gynecology. 207: 475.e1-475.e14. PMID 23111115 DOI: 10.1016/J.Ajog.2012.10.871  0.76
2012 Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenetics and Genomics. 22: 858-67. PMID 23080225 DOI: 10.1097/Fpc.0B013E32835A450B  0.76
2012 Acosta EP, Limoli KL, Trinh L, Parkin NT, King JR, Weidler JM, Ofotokun I, Petropoulos CJ. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrobial Agents and Chemotherapy. 56: 5938-45. PMID 22964257 DOI: 10.1128/Aac.00691-12  0.76
2012 Sandkovsky U, Swindells S, Robbins BL, Nelson SR, Acosta EP, Fletcher CV. Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection. Aids (London, England). 26: 2257-9. PMID 22948265 DOI: 10.1097/Qad.0B013E328359A978  0.76
2012 Nikanjam M, Kabamba D, Cressey TR, Burger D, Aweeka FT, Acosta EP, Spector SA, Capparelli EV. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrobial Agents and Chemotherapy. 56: 5374-80. PMID 22869579 DOI: 10.1128/Aac.00842-12  0.76
2012 McPherson C, Warner B, Hunstad DA, Elward A, Acosta EP. Oseltamivir dosing in premature infants. The Journal of Infectious Diseases. 206: 847-50. PMID 22807525 DOI: 10.1093/Infdis/Jis471  0.76
2012 Sandkovsky U, Swindells S, Moore R, Acosta EP, Fletcher CV. Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection. Pharmacotherapy. 32: 142-7. PMID 22392423 DOI: 10.1002/Phar.1015  0.8
2012 James AM, Ofotokun I, Sheth A, Acosta EP, King JR. Tenofovir: Once-daily dosage in the management of HIV infection Clinical Medicine Insights: Therapeutics. 4: 201-216. DOI: 10.4137/CMT.S8316  0.76
2011 Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Eron JJ. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). Aids (London, England). 25: 2113-22. PMID 21857490 DOI: 10.1097/Qad.0B013E32834Bbaa9  0.76
2011 King JR, Yogev R, Jean-Philippe P, Graham B, Wiznia A, Britto P, Carey V, Hazra R, Acosta EP. Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients. Antimicrobial Agents and Chemotherapy. 55: 4290-4. PMID 21670182 DOI: 10.1128/Aac.01334-10  0.76
2011 Ofotokun I, Lennox JL, Eaton ME, Ritchie JC, Easley KA, Masalovich SE, Long MC, Acosta EP. Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure. Journal of Clinical Pharmacology. 51: 1539-48. PMID 21209245 DOI: 10.1177/0091270010385118  0.76
2010 Acosta EP, Kimberlin DW. Determination of appropriate dosing of influenza drugs in pediatric patients Clinical Pharmacology and Therapeutics. 88: 704-707. PMID 20881956 DOI: 10.1038/Clpt.2010.173  0.76
2010 Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D, Haas DW. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. The Journal of Infectious Diseases. 202: 717-22. PMID 20662624 DOI: 10.1086/655470  0.76
2010 McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 50: 912-9. PMID 20156060 DOI: 10.1086/650749  0.76
2010 Overton ET, Tschampa JM, Klebert M, Royal M, Rodriguez M, Spitz T, Kim G, Mondy KE, Acosta EP. The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy. Journal of Clinical Pharmacology. 50: 1050-5. PMID 20147613 DOI: 10.1177/0091270009357431  0.76
2010 Megazzini KM, Sinkala M, Vermund SH, Redden DT, Krebs DW, Acosta EP, Mwanza J, Goldenberg RL, Chintu N, Bulterys M, Stringer JS. A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia. Aids (London, England). 24: 447-55. PMID 19926959 DOI: 10.1097/Qad.0B013E328334B285  0.76
2009 Ezzeldin HH, Acosta EP, Mattison LK, Fourie J, Modak A, Diasio RB. (13)C-5-FU breath test current status and future directions: a comprehensive review. Journal of Breath Research. 3: 047002. PMID 21386199 DOI: 10.1088/1752-7155/3/4/047002  0.76
2009 Bennetto-Hood C, Johnson VA, King JR, Hoesley CJ, Acosta EP. Novel methodology for antiretroviral quantitation in the female genital tract. Hiv Clinical Trials. 10: 193-9. PMID 19632958 DOI: 10.1310/Hct1003-193  0.36
2009 Redhage LA, Shintani A, Haas DW, Emeagwali N, Markovic M, Oboho I, Mwenya C, Erdem H, Acosta EP, Morrow JD, Hulgan T. Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults. Hiv Clinical Trials. 10: 181-92. PMID 19632957 DOI: 10.1310/Hct1003-181  0.76
2009 Bennetto-Hood C, Bryson YJ, Stek A, King JR, Mirochnick M, Acosta EP. Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. Hiv Clinical Trials. 10: 41-7. PMID 19362995 DOI: 10.1310/Hct1001-41  0.36
2009 Haas DW, Koletar SL, Laughlin L, Kendall MA, Suckow C, Gerber JG, Zolopa AR, Bertz R, Child MJ, Hosey L, Alston-Smith B, Acosta EP. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. Journal of Acquired Immune Deficiency Syndromes (1999). 50: 290-3. PMID 19194314 DOI: 10.1097/Qai.0B013E318189A7Df  0.76
2009 Long MC, King JR, Acosta EP. Pharmacologic aspects of new antiretroviral drugs. Current Hiv/Aids Reports. 6: 43-50. PMID 19149996 DOI: 10.1007/S11904-009-0007-Y  0.36
2009 King JR, Acosta EP, Yogev R, Wiznia A, Kraimer J, Graham B, Carey V, Britto P, Jean-Philippe P, Moye J, Watson D. Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients. The Pediatric Infectious Disease Journal. 28: 159-61. PMID 19106779 DOI: 10.1097/Inf.0B013E3181861D8B  0.36
2008 Khanlou H, Sayana S, Acosta E. No residual activity of raltegravir after development of 148 complex mutations in vivo. Journal of the International Association of Physicians in Aids Care (Chicago, Ill. : 2002). 7: 281-2. PMID 19164138 DOI: 10.1177/1545109708327489  0.76
2008 Long MC, King JR, Acosta EP. Pharmacologic aspects of new antiretroviral drugs. Current Infectious Disease Reports. 10: 522-9. PMID 18945395 DOI: 10.1007/S11908-008-0084-X  0.36
2008 Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, Zhou Y, Pitt E, Anderson KS, Acosta EP, Siliciano RF. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nature Medicine. 14: 762-6. PMID 18552857 DOI: 10.1038/Nm1777  0.76
2008 Collier AC, Tierney C, Downey GF, Eshleman SH, Kashuba A, Klingman K, Vergis EN, Pakes GE, Rooney JF, Rinehart A, Mellors JW. Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. Hiv Clinical Trials. 9: 91-102. PMID 18474494 DOI: 10.1310/Hct0902-91  0.76
2008 Kilby JM, Lee HY, Hazelwood JD, Bansal A, Bucy RP, Saag MS, Shaw GM, Acosta EP, Johnson VA, Perelson AS, Goepfert PA. Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline. Aids (London, England). 22: 957-62. PMID 18453855 DOI: 10.1097/Qad.0B013E3282Fbd1Da  0.76
2008 Ribaudo HJ, Kuritzkes DR, Lalama CM, Schouten JT, Schackman BR, Acosta EP, Gulick RM. Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. The Journal of Infectious Diseases. 197: 1006-10. PMID 18419537 DOI: 10.1086/529208  0.76
2008 Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP, Gulick RM. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. The Journal of Infectious Diseases. 197: 867-70. PMID 18269317 DOI: 10.1086/528802  0.76
2008 Ofotokun I, Acosta EP, Lennox JL, Pan Y, Easley KA. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. Pharmacotherapy. 28: 74-81. PMID 18154477 DOI: 10.1592/Phco.28.1.74  0.76
2008 Gerber JG, Kitch DW, Fichtenbaum CJ, Zackin RA, Charles S, Hogg E, Acosta EP, Connick E, Wohl D, Kojic EM, Benson CA, Aberg JA. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. Journal of Acquired Immune Deficiency Syndromes (1999). 47: 459-66. PMID 17971707 DOI: 10.1097/Qai.0B013E31815Bace2  0.32
2008 King J, Acosta E. Pediatric clinical pharmacology and its implications for antiretroviral drug development Current Opinion in Hiv and Aids. 3: 272-276. DOI: 10.1097/Coh.0B013E3282F64530  0.76
2007 Tremoulet AH, Capparelli EV, Patel P, Acosta EP, Luzuriaga K, Bryson Y, Wara D, Zorrilla C, Holland D, Mirochnick M. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrobial Agents and Chemotherapy. 51: 4297-302. PMID 17893155 DOI: 10.1128/Aac.00332-07  0.76
2007 Riddler SA, Jiang H, Tenorio A, Huang H, Kuritzkes DR, Acosta EP, Landay A, Bastow B, Haas DW, Tashima KT, Jain MK, Deeks SG, Bartlett JA. A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antiviral Therapy. 12: 531-41. PMID 17668562  0.76
2007 Bennetto-Hood C, Aldrovandi GM, King JR, Woodman K, Ashouri N, Acosta EP. Persistence of nevirapine in breast milk after discontinuation of treatment. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 45: 391-4. PMID 17599320 DOI: 10.1086/519427  0.36
2007 Acosta EP, Kendall MA, Gerber JG, Alston-Smith B, Koletar SL, Zolopa AR, Agarwala S, Child M, Bertz R, Hosey L, Haas DW. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrobial Agents and Chemotherapy. 51: 3104-10. PMID 17576825 DOI: 10.1128/Aac.00341-07  0.76
2007 Parks DA, Jennings HC, Taylor CW, Acosta EP. Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. Aids (London, England). 21: 1373-5. PMID 17545719 DOI: 10.1097/Qad.0B013E328133F068  0.76
2007 Zorrilla CD, Van Dyke R, Bardeguez A, Acosta EP, Smith B, Hughes MD, Huang S, Watts DH, Heckman B, Jiménez E, McSherry G, Mofenson L. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. Antimicrobial Agents and Chemotherapy. 51: 2208-10. PMID 17420209 DOI: 10.1128/Aac.00871-06  0.76
2007 Acosta EP, Brundage RC, King JR, Sánchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud G, Whitley R, Kimberlin DW. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clinical Pharmacology and Therapeutics. 81: 867-72. PMID 17392728 DOI: 10.1038/Sj.Clpt.6100150  0.76
2007 King JR, Kakuda TN, Paul S, Tse MM, Acosta EP, Becker SL. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers. Journal of Clinical Pharmacology. 47: 201-8. PMID 17244771 DOI: 10.1177/0091270006296763  0.76
2007 Prasain JK, Peng N, Acosta E, Moore R, Arabshahi A, Meezan E, Barnes S, Wyss JM. Pharmacokinetic study of puerarin in rat serum by liquid chromatography tandem mass spectrometry. Biomedical Chromatography : Bmc. 21: 410-4. PMID 17221935 DOI: 10.1002/Bmc.772  0.76
2007 Kshirsagar SA, Blaschke TF, Sheiner LB, Krygowski M, Acosta EP, Verotta D. Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria. Journal of Pharmacokinetics and Pharmacodynamics. 34: 35-55. PMID 17004125 DOI: 10.1007/S10928-006-9032-2  0.76
2006 Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM. Design issues in initial HIV-treatment trials: focus on ACTG A5095. Antiviral Therapy. 11: 751-60. PMID 17310819  0.76
2006 Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. Jama. 296: 769-81. PMID 16905783 DOI: 10.1001/Jama.296.7.769  0.76
2006 King JR, Acosta EP. Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clinical Pharmacokinetics. 45: 665-82. PMID 16802849 DOI: 10.2165/00003088-200645070-00003  0.76
2006 Wu H, Huang Y, Acosta EP, Park JG, Yu S, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JG. Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. Journal of Pharmacokinetics and Pharmacodynamics. 33: 399-419. PMID 16583266 DOI: 10.1007/S10928-006-9006-4  0.32
2006 Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 42: 401-7. PMID 16392089 DOI: 10.1086/499364  0.8
2005 Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaudo H, Gulick RM. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Annals of Internal Medicine. 143: 714-21. PMID 16287792 DOI: 10.7326/0003-4819-143-10-200511150-00008  0.76
2005 Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, Martinez A, Jiang H, Gulick RM. Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. Journal of Acquired Immune Deficiency Syndromes (1999). 40: 301-6. PMID 16249704 DOI: 10.1097/01.Qai.0000180078.53321.6A  0.76
2005 King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Hughes MD, Chen J, Wiznia A, Damle B, Acosta EP. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. The Pediatric Infectious Disease Journal. 24: 880-5. PMID 16220085 DOI: 10.1097/01.Inf.0000180508.21918.8A  0.76
2005 Wu H, Huang Y, Acosta EP, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JG. Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. Journal of Acquired Immune Deficiency Syndromes (1999). 39: 272-83. PMID 15980686 DOI: 10.1097/01.Qai.0000165907.04710.Da  0.32
2005 King JR, Gerber JG, Fletcher CV, Bushman L, Acosta EP. Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. Aids (London, England). 19: 1059-63. PMID 15958837 DOI: 10.1097/01.Aids.0000174452.78497.54  0.8
2005 Kashuba AD, Tierney C, Downey GF, Acosta EP, Vergis EN, Klingman K, Mellors JW, Eshleman SH, Scott TR, Collier AC. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. Aids (London, England). 19: 145-52. PMID 15668539 DOI: 10.1097/00002030-200501280-00006  0.76
2004 King JR, Yogev R, Aldrovandi G, Chadwick E, Acosta EP. Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube. Hiv Clinical Trials. 5: 288-93. PMID 15562369 DOI: 10.1310/Grqx-761M-Dpb1-V9Cg  0.36
2004 Acosta EP, Wu H, Hammer SM, Yu S, Kuritzkes DR, Walawander A, Eron JJ, Fichtenbaum CJ, Pettinelli C, Neath D, Ferguson E, Saah AJ, Gerber JG. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. Journal of Acquired Immune Deficiency Syndromes (1999). 37: 1358-66. PMID 15483465 DOI: 10.1097/00126334-200411010-00004  0.32
2004 Swanstrom R, Bosch RJ, Katzenstein D, Cheng H, Jiang H, Hellmann N, Haubrich R, Fiscus SA, Fletcher CV, Acosta EP, Gulick RM. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. The Journal of Infectious Diseases. 190: 886-93. PMID 15295692 DOI: 10.1086/422692  0.76
2004 Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. The New England Journal of Medicine. 350: 1850-61. PMID 15115831 DOI: 10.1056/Nejmoa031772  0.76
2004 King JR, Wynn H, Brundage R, Acosta EP. Pharmacokinetic enhancement of protease inhibitor therapy. Clinical Pharmacokinetics. 43: 291-310. PMID 15080763 DOI: 10.2165/00003088-200443050-00003  0.36
2004 Stringer JS, Sinkala M, Goldenberg RL, Kumwenda R, Acosta EP, Aldrovandi GM, Stout JP, Vermund SH. Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings. Aids (London, England). 18: 939-43. PMID 15060442 DOI: 10.1097/00002030-200404090-00012  0.76
2004 Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. The Journal of Infectious Diseases. 189: 1176-84. PMID 15031785 DOI: 10.1086/382754  0.76
2004 Dubuisson JG, King JR, Stringer JS, Turner ML, Bennetto C, Acosta EP. Detection of nevirapine in plasma using thin-layer chromatography. Journal of Acquired Immune Deficiency Syndromes (1999). 35: 155-7. PMID 14722448 DOI: 10.1097/00126334-200402010-00009  0.36
2004 Bennetto CJ, King JR, Turner ML, Stringer JS, Acosta EP. Effects of concentration and temperature on the stability of nevirapine in whole blood and serum. Clinical Chemistry. 50: 209-11. PMID 14709651 DOI: 10.1373/Clinchem.2003.026492  0.36
2003 Goetzman ES, Tian L, Nagy TR, Gower BA, Schoeb TR, Elgavish A, Acosta EP, Saag MS, Wood PA. HIV protease inhibitor ritonavir induces lipoatrophy in male mice. Aids Research and Human Retroviruses. 19: 1141-50. PMID 14709251 DOI: 10.1089/088922203771881248  0.76
2003 Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, Acosta EP, Taylor KH, Carter J, Saag MS. Duration of highly active antiretroviral therapy regimens. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 37: 714-22. PMID 12942406 DOI: 10.1086/377271  0.76
2003 Stringer JS, Sinkala M, Chapman V, Acosta EP, Aldrovandi GM, Mudenda V, Stout JP, Goldenberg RL, Kumwenda R, Vermund SH. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. Aids (London, England). 17: 1659-65. PMID 12853748 DOI: 10.1097/00002030-200307250-00010  0.76
2003 Acosta EP, Balfour HH. Intermittent administration of high-dose stavudine to nucleoside-experienced individuals infected with HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999). 33: 343-8. PMID 12843745 DOI: 10.1097/00126334-200307010-00008  0.76
2003 Gerber JG, Acosta EP. Therapeutic drug monitoring in the treatment of HIV-infection Journal of Clinical Virology. 27: 117-128. PMID 12829033 DOI: 10.1016/S1386-6532(03)00033-7  0.76
2003 Stringer JS, Sinkala M, Stout JP, Goldenberg RL, Acosta EP, Chapman V, Kumwenda-Phiri R, Vermund SH. Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. Journal of Acquired Immune Deficiency Syndromes (1999). 32: 506-13. PMID 12679702 DOI: 10.1097/00126334-200304150-00007  0.76
2003 King JR, Acosta EP, Chadwick E, Yogev R, Crain M, Pass R, Kimberlin DW, Sturdevant MS, Aldrovandi GM. Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients. The Pediatric Infectious Disease Journal. 22: 239-44. PMID 12634585 DOI: 10.1097/01.Inf.0000055093.42130.40  0.36
2003 Acosta EP, King JR. Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 36: 373-7. PMID 12539082 DOI: 10.1086/345993  0.76
2003 Turner ML, Reed-Walker K, King JR, Acosta EP. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 784: 331-41. PMID 12505781 DOI: 10.1016/S1570-0232(02)00822-X  0.36
2002 King JR, Kimberlin DW, Aldrovandi GM, Acosta EP. Antiretroviral pharmacokinetics in the paediatric population: a review. Clinical Pharmacokinetics. 41: 1115-33. PMID 12405863 DOI: 10.2165/00003088-200241140-00001  0.36
2002 Chen RY, Westfall AO, Raper JL, Cloud GA, Chatham AK, Acosta EP, Pham SV, Tolson JM, Heudebert GR, Saag MS. Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. Aids Research and Human Retroviruses. 18: 909-16. PMID 12230934 DOI: 10.1089/088922202760265588  0.76
2002 Acosta EP, Fletcher CV, Flexner C, Haas D, Hall S, Hamzeh F, Haubrich R, Kashuba A, Katzenstein D, Lawrence J, Lertora J, Gerber JG, Para M, Rosenkranz S, Sheiner L, et al. Position paper on therapeutic drug monitoring of antiretroviral agents Aids Research and Human Retroviruses. 18: 825-834. PMID 12201904 DOI: 10.1089/08892220260190290  0.76
2002 Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. The Journal of Infectious Diseases. 186: 626-33. PMID 12195349 DOI: 10.1086/342681  0.76
2002 Pereira AS, Smeaton LM, Gerber JG, Acosta EP, Snyder S, Fiscus SA, Tidwell RR, Gulick RM, Murphy RL, Eron JJ. The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). The Journal of Infectious Diseases. 186: 198-204. PMID 12134255 DOI: 10.1086/341209  0.76
2002 Acosta EP. Pharmacokinetic enhancement of protease inhibitors Journal of Acquired Immune Deficiency Syndromes. 29. PMID 11832697 DOI: 10.1097/00126334-200202011-00003  0.76
2001 Gulick RM, Smeaton LM, D’Aquila RT, Eron JJ, Currier JS, Gerber JG, Acosta E, Sommadossi J, Tung R, Snyder S, Kuritzkes DR, Murphy RL. Indinavir, Nevirapine, Stavudine, and Lamivudine for Human Immunodeficiency Virus–Infected, Amprenavir-Experienced Subjects: AIDS Clinical Trials Group Protocol 373 The Journal of Infectious Diseases. 183: 715-721. PMID 11181147 DOI: 10.1086/318820  0.32
2001 Kakuda TN, Page LM, Anderson PL, Henry K, Schacker TW, Rhame FS, Acosta EP, Brundage RC, Fletcher CV. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir Antimicrobial Agents and Chemotherapy. 45: 236-242. PMID 11120972 DOI: 10.1128/Aac.45.1.236-242.2001  0.76
2000 Fletcher CV, Acosta EP, Cheng H, Haubrich R, Fischl M, Raasch R, Mills C, Hu XJ, Katzenstein D, Remmel RP, Gulick RM. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884 Aids. 14: 2495-2501. PMID 11101060 DOI: 10.1097/00002030-200011100-00011  0.76
2000 Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359 Journal of Infectious Diseases. 182: 1375-1384. PMID 11023461 DOI: 10.1086/315867  0.76
2000 Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors Clinical Infectious Diseases. 30. PMID 10860900 DOI: 10.1086/313852  0.76
1999 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy. 19: 708-12. PMID 10391416 DOI: 10.1592/Phco.19.9.708.31544  0.8
1999 Fletcher CV, Kakuda TN, Page LM, Acosta EP, Brundage RC, Anderson PL, Henry K, Schacker T. Pharmacokinetic strategies for concentration-targeted therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV) Clinical Pharmacology and Therapeutics. 65: 161. DOI: 10.1016/S0009-9236(99)80174-X  0.76
1998 Kakuda TN, Acosta EP, Fletcher CV. Potential confusion with antiretroviral drugs American Journal of Health-System Pharmacy. 55: 2639-2640. PMID 9872703 DOI: 10.1093/Ajhp/55.24.2639  0.76
1998 Fletcher CV, Acosta EP, Henry K, Page LM, Gross CR, Kawle SP, Remmel RP, Erice A, Balfour HH. Concentration-controlled zidovudine therapy. Clinical Pharmacology and Therapeutics. 64: 331-8. PMID 9757157 DOI: 10.1016/S0009-9236(98)90182-5  0.76
1997 Acosta EP, Henry K, Page LM, Erice A, Balfour HH, Fletcher CV. Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy. Pharmacotherapy. 17: 424-430. DOI: 10.1002/J.1875-9114.1997.Tb03052.X  0.8
1996 Balfour HH, Fletcher CV, Erice A, Henry WK, Acosta EP, Smith SA, Holm MA, Boivin G, Shepp DH, Crumpacker CS, Eaton CA, Martin-Munley SS. Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Antimicrobial Agents and Chemotherapy. 40: 2721-6. PMID 9124829 DOI: 10.1128/Aac.40.12.2721  0.76
1996 Acosta EP, Page LM, Fletcher CV. Clinical pharmacokinetics of zidovudine. An update. Clinical Pharmacokinetics. 30: 251-62. PMID 8983858 DOI: 10.2165/00003088-199630040-00001  0.8
1996 Acosta EP, Schwebke K, Henry K, Fletcher CV. Disposition of zidovudine in obese pregnant women with human immunodeficiency virus type 1 infection. The Journal of Infectious Diseases. 174: 673. PMID 8769638 DOI: 10.1093/Infdis/174.3.673  0.8
1995 Acosta EP, Fletcher CV. Antiretroviral drug interactions. International Journal of Antimicrobial Agents. 5: 73-83. PMID 18611653 DOI: 10.1016/0924-8579(94)00063-Z  0.8
1995 Schwebke K, Fletcher CV, Acosta EP, Henry K. Pentamidine concentrations in a mother with AIDS and in her neonate. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 20: 1569-70. PMID 7548518 DOI: 10.1093/Clinids/20.6.1569  0.8
1995 Acosta EP, Fletcher CV. Antiretroviral drug interactions International Journal of Antimicrobial Agents. 5: 73-83. DOI: 10.1016/0924-8579(94)00063-Z  0.76
1994 Fletcher CV, Acosta EP, Strykowski JM. Gender differences in human pharmacokinetics and pharmacodynamics. The Journal of Adolescent Health : Official Publication of the Society For Adolescent Medicine. 15: 619-29. PMID 7696281 DOI: 10.1016/S1054-139X(94)90628-9  0.8
1993 Larsen JS, Acosta EP. Leukotriene-receptor antagonists and 5-lipoxygenase inhibitors in asthma. The Annals of Pharmacotherapy. 27: 898-903. PMID 8364276 DOI: 10.1177/106002809302700718  0.76
Show low-probability matches.